Diagnostic technique for infective renal pathology |
|
|
IPC classes for russian patent Diagnostic technique for infective renal pathology (RU 2539386):
Differential diagnostic technique for cervical dysplasia and cervical cancer / 2538618
Invention refers to medicine and aims at differential diagnostics of cervical dysplasia and cervical cancer. The cervical biopsy material is taken. If a cytological examination shows cervical dysplasia, RNA is recovered from the tissue sample, and iRNA expression of the c-fos gene is analysed in relation to the TATA-related protein (TBP) with using qualitative PCR. If the ratio of iRNA expression of the c-fos gene to TBP iRNA is from 109 to 145 relative units, severe dysplasia is diagnosed; if the related ratio falls within the range of 18 to 35 standard units, pre-invasive cervical cancer (cancer in situ) is diagnosed; the ratio falling within the range of 148 to 208 relative units enables diagnosing squamous microinvasive cervical cancer; the derived value exceeding 208 standard units, squamous invasive cervical cancer is diagnosed.
 Method of determining biological inequivalence of nanodiamonds / 2538611
Incubation medium, oxidation substrate and tetraphenylphpsphonium chloride as indicator are placed into respective measuring cell of installation for measuring mitochondria potential, provided with tetraphenylphosphonium-selective electrode, change of tetraphenylphosphonium concentration is registered and when constant tetraphenylphosphonium concentration is achieved, mitochondria, isolated from animal organism, are added. Change of membrane potential of mitochondria is registered by change of electrode signal, when constant potential is achieved, respective water suspensions of analysed samples of nanodiamonds with pH 7.2-7.4 are added, and value of rate of change of mitochondria membrane potential is measured. Presence of statistically reliable difference of rates of mitochondria membrane potential change testifies to biological inequivalence of compared samples of nanodiamonds.
Diagnostic technique for traumatic microinjury of pulmonary tissue in post-mortem examination / 2537212
Hose of an artificial air feed apparatus is inserted into a lobar bronchus of the estimated injured lobe of the lung. The hose is fixed by ligaturing the bronchus. The air is pumped into the examined lobe of the collapsed lung until it extends completely, and a microinjury is visualised.
 Method of determining procaine in blood plasma / 2537179
Invention relates to biology, forensic and analytical chemistry and specifically to methods of determining procaine in blood plasma. The method comprises adding sodium fluoride to blood plasma containing procaine to achieve concentration of 10 mg/ml; treating the obtained mixture with acetone; separating the extract from the precipitate by filtering; evaporating acetone from the filtrate in an air current at room temperature; diluting the aqueous residue by adding water; saturating the obtained solution with ammonium sulphate; alkalising with an ammonium buffer solution to pH 9.0-9.5; extracting twice with portions of an organic extraction agent in the form of 30% camphor solution in methyl acetate, with ratio of the aqueous to the organic phase of 1:1 by volume; separating the organic extracts; combining; evaporating the solvent from the combined extract in an air current at room temperature; chromatographing the residue in a thin layer of silica gel STKH-1A on Sorbfil PTSKH-AF-A-UF plates, using a dichloromethane-ethanol mobile phase in ratio of 6:4 by volume; developing the chromatogram in UV light; eluting the analysed substance from the sorbent with a mixture of acetonitrile-methanol-0.025 M potassium dihydrogen phosphate solution with pH 3.0 in ratio of 10:10:90 by volume; chromatographing by HPLC method using a reversed-phase sorbent Nucleosil C18, a polar mobile phase acetonitrile-methanol-0.025 M potassium dihydrogen phosphate solution with pH 3.0 in ratio of 10:10:90 by volume and a UV detector; measuring optical density at wavelength 298 nm and calculating the amount of the analysed compound from the area of the chromatographic peak.
 Method for examining liver detoxification function state / 2537163
Invention refers to medicine, namely to hepatology, and describes a method for examining the liver detoxification function state. The method involves measuring fasting blood AWM (average weigh molecule), ALT (alanine aminotransferase) and AST (aspartate aminotransferase), measuring the same values the night before at bedtime, as well as measuring a circulating blood volume and a packed cell volume in the morning and in the evening followed by determining a coefficient of the liver detoxification function state; and if observing the derived coefficient K≤0.6, the liver detoxification function state is considered to be satisfactory, while the coefficient K>0.6 shows the depressed liver detoxification function.
Method for microorganism adhesive potential rapid test / 2537128
Method involves the preliminary sorption of a specific ligand in polystyrene tray wells; the above ligand is specified in: haemoglobin, myoglobin, collagen, fibrinogen, fibronectin, immunoglobulin A; that is followed by adding a microorganism cell suspension into the tray wells with the sorbed ligand, incubating the cell suspension in the tray wells for 15 minutes, sampling a suspension aliquot from the well and adding it to wells of another or the same tray containing 0.5% sodium chloride or 0.2 M sodium phosphate; the bacterial cell adhesion is assessed by measuring a decrease of the optical density of the prepared diluted suspensions at wave length 600 nm as compared to the well references free from ligands.
 Method of determining substituted 2-methoxyhydroxybenzene in biological material / 2537125
Invention relates to biology and toxicological chemistry and can be used in practice of sanitary and epidemiological stations, chemical-toxicological, forensic and veterinary laboratories. A biological material, containing substituted 2-methoxyhydroxybenzene, is two times (each time for 30 minutes) infused with ethylacetate with mixing, separate extracts are separated from solid particles of the biological material, combined, ethylacetate is evaporated in an air flow at 18-22°C, residue is repeatedly processed with acetone, acetone extracts are separated, combined, dehydrated, evaporated in an air flow at 18-22°C, and then in a nitrogen flow until a solvent is completely removed, residue is dissolved in hexane, extracted with a buffer solution with pH 12-13, a water-alkaline extraction is separated, acidified to pH 2-3, saturated with sodium sulphate, extracted with diethyl ether, the ether extract is separated, dehydrated, evaporated in an air flow at 18-22°C, and then - in a nitrogen flow until the solvent is completely removed, residue is dissolved in a mixture of solvents hexane-dioxane-propanol-2, taken in a ratio of 20:5:1 by volume, chromatographed in macrocolumn with silicagel KSS No 3 80/120 mcm with the application of a mobile phase hexane-dioxane-propanol-2 in a ratio of 20:5:1 by volume, eluate fractions, containing the analysed substance, are combined, the eluent is evaporated first in an air flow at a temperature of 18-22°C, and then in a nitrogen flow until the solvent is completely removed, residue is dissolved in dichloromethane, processed for 20 minutes with N-tert-butyl-dimethylsilyl-N-methyltrifluoroacetamide under conditions of heating at a temperature of 60°C with carrying out determination by a chromatography-mass spectrometry method with the application of a capillary column 25 m long with an internal diameter of 0.2 mm with an immobile phase (5%-phenyl)-methylpolysiloxane, with the application of a mass-selective detector, working in an electron impact mode, an initial temperature of the column thermostat constitutes 70°C, the said temperature is kept for 3 minutes, further the temperature is programmed from 70°C to 290°C at a rate of 20°C per minute, the final column temperature is kept for 10 minutes, the injector temperature constitutes 250°C, the quadrupole temperature is 150°C, the temperature of a ion source is 230°C, the temperature of the detector interface is 300°C, intensity of a signal, conditioned by charged particles, formed in the bombardment of the analysed substance, leaving the capillary column and getting into the ion source, with a ionising beam of electrons with the energy of 70 eV, is registered, the mass-spectrum by the complete ion flow is registered and an amount of substituted 2-methoxyhydroxybenzene is calculated by the area of a chromatographic peak of its trimethylsilyl derivative.
 Method of determining n-(4-nitro-2-phenoxyphenyl)-methanesulphonamide in biological material / 2537121
Invention relates to biology and toxicological chemistry and can be used in chemical-toxicology, expert forensic and clinical laboratories. The method includes: crushing a biological object containing N-(4-nitro-2-phenoxyphenyl)-methanesulphonamide, settling twice for 45 minutes with portions of an organic isolating agent which is methyl acetate, combining the obtained extracts, evaporating the solvent from the resultant extract, treating the residue with acetone, separating the acetone extract, evaporating the solvent from resultant extract, dissolving the residue in diethyl ether, extracting the ether solution with a buffer solution at pH 9-10, acidifying the aqueous alkaline extract with 24% hydrochloric acid to pH 2-3, saturating the obtained solution with sodium bromide, extracting with ethyl acetate, evaporating the obtained extract in an air current at 20-22°C until a dry residue is obtained, dissolving the residue in a mixture of hexane and acetone taken in volume ratio of 8:2, performing chromatography on a macrocolumn with silica gel L 40/100 mcm using a hexane-acetone mobile phase in volume ratio of 8:2, combining eluate fractions containing the analysed substance, evaporating the eluent in an air current at 20-22°C until complete removal of the solvent, dissolving the residue in methanol and performing determination via a combined physical-chemical method in the form of chromatography-mass spectrometry, using a DB-5 MS EVIDEX capillary column with a mobile phase which is 5% phenyl-95% methylpolysiloxane, using a mass-selective detector operating in electron impact mode, the initial thermostat temperature of the column is 70°C, maintaining said temperature for 3 minutes, further raising the temperature from 70°C to 290°C at a rate of 20°C per minute, maintaining the final temperature of the column for 16 minutes, the temperature of the injector is 250°C, the temperature of the quadrupole is 150°C, the temperature of the detector interface is 300°C, detecting strength of the signal resulting from charged particles formed when bombarding the analysed substance coming from the capillary column and falling into an ion source with an ionising electron beam with energy of 70 eV, recording the mass spectrum on the full ion current, while calculating the amount of N-(4-nitro-2-phenoxyphenyl)-methanesulphonamide from the area of the chromatographic peak.
 Method of obtaining standard quality sample of saliva facia for crystallography / 2536950
Invention relates to medicine, namely to clinical, laboratory diagnostics, microbiological methods of research, and is aimed at standardisation of saliva analysis by method of wedge dehydration/crystallography. Claimed is method of obtaining standard, quality sample of mixed saliva facia for crystallography with application of portable laboratory device with inbuilt levels on axes X and Y, legs, regulated by height and isolating cover. From 20 to 40 microscope slides are simultaneously placed on the surface of portable laboratory device after obtaining smooth horizontal without inclination angle surface. After that, one sample of mixed saliva in amount 0.02 ml, preliminarily centrifuged for 20 min at 3000 rev/min, is applied on each microscope slide by means of micropipette. As a result a round 1.0 mm high drop of mixed saliva with diameter from 4.0 to 5.0 mm, corresponding to standard parameters, is obtained. Then, standard in dimensions drop on microscope slide placed on the surface of portable laboratory device, adjusted by levels, is dried at room temperature +18…+25°C under isolating cover for 5 hours, with further performance of microscopy of standard quality sample of saliva facia.
 Method for measuring maximum allowable blood concentration of heavy metals in children after integrated exposure / 2536268
Invention aims at asserting the maximum allowable blood concentrations (MAC) of heavy metals in the children living in the dirty environment as shown by health risk criteria after the chronic integrated exposure. An environmentally neglected zone is selected; a representative sampling of the children for the examination is drawn that is a basic group with using biological, social and hygienic criteria; the same criteria are used to draw a representative sampling of the children to a reference group living in the environmentally friendly zone. In the territory of the above zones, the chronic exposure of the analysed heavy metal is qualitatively assessed by establishing its average daily concentration in the ambient environment; the derived value is used to calculate a total average daily doses of a heavy metal supplied from various sources into a child's body averaged over the annual exposure for the children of both groups. Blood is sampled from the children every three months for one year to determine the content of the analysed heavy metal and also to measure the biochemical values of blood plasma and serum characterizing body responses presented by actual or potential health problems that are response markers. That is followed by calculating the average blood concentration of the analysed heavy metal and comparing it to the reference for the same heavy metal with using a Student two-sample test, thereby stating whether the children were sampled from the main and reference groups adequately. A mathematical modelling procedure is used to establish a relation between the exposure that is the total average daily doses of the analysed metal, and the exposure marker that is the average blood metal concentration. A sliding window technology is used to assert the response markers selected. The maximum allowable concentration of the exposure marker and respective marker is determined by a technique based on ratio analysis.
Method for evaluating the severity of pathological process flow at chronic diffuse hepatic lesions / 2244305
One should detect the level of hepato-specific enzymes (HSE) in blood plasma, such as: urokinase (UK), histidase (HIS), fructose-1-phosphataldolase (F-1-P), serine dehydratase (L-SD), threonine dehydratase (L-TD) and products of lipid peroxidation (LP), such as: dienic conjugates (DC), malonic dialdehyde (MDA). Moreover, one should detect the state of inspecific immunity parameters, such as: immunoregulatory index (IRI) as the ratio of T-helpers and T-suppressors, circulating immune complexes (CIC). Additionally, one should evaluate the state of regional circulation by applying rheohepatography (RHG), the system of microhemocirculation with the help of conjunctival biomicroscopy (CB) to detect intravascular index (II). In case of increased UK, HIS levels up to 0.5 mcM/ml/h, F-1-P, L-SD, L-Td, LP products, CIC by 1.5 times, higher IRI up to 2 at the norm being 1.0-1.5, altered values of regional circulation, increased II up to 2 points at the norm being 1 point, not more one should diagnose light degree of process flow. At increased level of UK, HIS up to 0.75 mcM/ml/h, F-1-P, L-SD, L-TD, LP products, CIC by 1.5-2 times, increased IRI up to 2.5, altered values of regional circulation, increased II up to 3-4 points one should diagnose average degree of process flow. At increased level of UK, HIS being above 0.75 mcM/ml/h, F-1-P, L-SD, L-TD, LP products, CIC by 2 and more times, increased IRI being above 2.5, altered values of regional circulation, increased II up to 5 points and more one should diagnose severe degree of process flow.
Method for predicting cirrhosis at chronic viral hepatitis / 2244306
In hepatic bioptate one should detect products of lipid peroxidation (LP), such as: dienic conjugates (DC), activity of antioxidant enzymes, such as: catalase (CAT)and superoxide dismutase (SOD). One should calculate by the following formula: C = DC/(SOD x CAT)x100, where DC - the content of dienic conjugates, SOD - activity of superoxide dismutase, CAT - activity of catalase. At coefficient (C) values being above 65 one should predict high possibility for appearance of cirrhosis, at 46-645 - moderate possibility and at 14-45 -low possibility for appearance of cirrhosis.
 Method for predicting the result of acute peroral intoxication with cauterizing liquids / 2244930
At patient's hospitalization one should gather the data of clinical and laboratory values: on the type of chemical substance, patient's age, data of clinical survey and laboratory values: body temperature, the presence or absence of dysphonia, oliguria being below 30 ml/h, hemoglobinuria, erythrocytic hemolysis, exotoxic shock, glucose level in blood, fibrinogen and creatinine concentration in blood serum, general bilirubin, prothrombin index (PTI), Ph-plasma, the state of blood clotting system. The state of every sign should be evaluated in points to be then summed up and at exceeding the sum of points being above "+20" one should predict unfavorable result. At the sum of "-13" prediction should be stated upon as favorable and at "-13" up to "+20" - prediction is considered to be doubtful.
 Method for detecting disease duration in children with chronic obstructive pyelonephritis (variants) / 2245548
Disease duration in case of obstructive pyelonephritis should be detected by two ways: either by detecting the value of NADPH-diaphorase activity, as the marker of nitroxide synthase activity in different renal department and comparing it to established norm, or by detecting clinico-laboratory values, such as: hemoglobin, leukocytes, eosinophils, urea, beta-lipoproteides, lymphocytes, neutrophils, the level of glomerular filtration, that of canalicular reabsorption, urinary specific weight, daily excretion of oxalates, arterial pressure, and estimating their deviation against average statistical values by taking into account a child's age.
Method for predicting bronchial obstruction at chronical bronchitis / 2245550
One should carry out complex estimation of interleukin-1β) concentration in blood, saliva, bronchoalveolar liquid. Moreover, one should detect distribution coefficient (DC) for IL-1β as the ratio of IL-1β blood content to IL-1β salivary content. At increased IL-1β blood content by 10 times and more, by 2 times in saliva, unchanged level of bronchoalveolar IL-1β, at DC for IL-1β being above 1.0 one should predict bronchial obstruction. The method enables to conduct diagnostics of the above-mentioned disease at its earlier stages.
 Method for predicting oncological diseases / 2245551
The present innovation deals with genetic trials, with diagnostic field of oncological diseases due to analyzing DNA by altered status of gene methylation that take part in intracellular regulation of division, differentiating, apoptosis and detoxication processes. One should measure the status of methylation in three genes: p16, E-cadherine and GSTP1 in any human biological samples taken out of blood plasma, urine, lymph nodes, tumor tissue, inter-tissue liquid, ascitic liquid, blood cells and buccal epithelium and other; one should analyze DNA in which modified genes of tumor origin or their components are present that contain defective genes, moreover, analysis should be performed due to extracting and purifying DNA out of biological samples followed by bisulfite treatment of this DNA for modifying unprotected cytosine foundations at keeping 5-methyl cytosine being a protected cytosine foundation followed by PCR assay of bisulfite-treated and bisulfite-untreated genes under investigation and at detecting alterations obtained according to electrophoretic result of PCR amplificates, due to detecting the difference in the number and electrophoretic mobility of corresponding fractions at comparing with control methylated and unmethylated samples containing normal and hypermethylated forms of genes one should diagnose oncological diseases. The method provides higher reliability in detecting tumors, detection of remained tumor cells after operation.
Method for predicting the flow of gastric and duodenal ulcerous disease / 2246731
One should carry out diagnostic studying, moreover, on the 5th -6th d against the onset of exacerbation in case of gastric and duodenal ulcerous disease one should detect the content serotonin, histamine and acetylcholine in blood, then during 2-3 wk one should conduct medicinal therapy to detect serotonin, histamine and acetylcholine level in blood again and at serotonin content being by 2-3 times above the norm, histamine - by 1.15-1.4 times above the norm and acetylcholine - by 20-45% being below the norm one should predict the flow of gastric and duodenal ulcerous disease as a non-scarring ulcer.
 Method for predicting clinical course of pyo- inflammatory disease in extremities / 2247378
Method involves taking blood from ulnar vein (systemic blood circulation) and from large vein of the injured extremity proximal with respect to lesion focus (regional blood circulation). Spontaneous NST-test value is determined and difference is calculated in systemic and regional blood circulation as regional-to-systemic difference. The difference value is used for predicting clinical course of pyo-inflammatory disease in extremities.
Method for detecting efficiency of apitherapy in case of ulcerous duodenal disease / 2247568
One should introduce biologically active substance, moreover, in patient's blood serum one should detect the content of acetyl choline and choline esterase activity followed by 2-h-long intragastric pH-metry at loading with biologically active substance as warm 40-45%-honey water solution at 35-40 C, and at increased content of acetyl choline being above 1.0 mM/l, choline esterase being above 0.5 mM/l/30 min and pH level being 6.0-6.9 it is possible to consider apitherapy to be useful for treating ulcerous duodenal disease.
Method for quick test diagnostics of pharmacological sensitivity to inhibitors of gastric secretion / 2247981
It has been suggested a new method to detect pharmacological sensitivity to preparations as acidosuppressors. After the intake of the preparation a patient should undergo fibrogastroduodenoscopy 3 h later, then, through endoscopic catheter one should introduce 0.3%-Congo red solution intragastrically and the test is considered to be positive at keeping red color that indicates good sensitivity to the given preparation, and in case of dark-blue or black color the test is considered to be negative that indicates resistance to this preparation. The suggested innovation widens the number of diagnostic techniques of mentioned indication.
|
FIELD: medicine. SUBSTANCE: invention refers to medicine, namely to a diagnostic technique for infective renal pathology caused by Chlamydia trachomatis. Substance of the method consists in gas chromatographic and mass-spectrometric urine analysis for 2-propanamide, N-amino-oxymethylamide, 2-methyl-5-(1-methyl-ethyl)-phenol and 4-4-dihydrooxy-diphenyl-sulphone, and if the measured amounts are 0.002-0.06 mmole/l; 0.002-0.06 mmole/l; 0.003-0.11 mmole/l and 0.002-0.05 mmole/l respectively, an infective renal pathology caused by Chlamydia trachomatis is diagnosed. EFFECT: using the declared technique provides the non-invasive and informative early pre-manifestation diagnosis of the specific infective renal pathology caused by Chlamydia trachomatis. 5 ex
The invention relates to medicine, namely to infectious diseases, Nephrology and dermatology. Early etiological diagnosis of specific infectious renal pathology is important to ensure the effectiveness of its treatment. You know the identification of sediments Chlamydia trachomatis in glomerular area and localization of antigens of this type of chlamydia in the interstitial space lifetime obtained needle biopsies in patients with IgA nephropathy. The study of Chlamydia trachomatis antigen in tissue was performed using monoclonal antibodies (rakityansky I. A., Ryabov ie, the Role of Chlamydia trachomatis renal tissue in the pathogenesis of IgA nephropathy taking into account the patient's age // Journal of Infectology. - 2012. - So 4, No. 1. - S. 29-35. The main disadvantages are the counterpart of its invasiveness and loss of use for early, before the manifestation of clinical manifestations diagnosis of specific infectious diseases of the kidney, caused by Chlamydia trachomatis. The closest analogue prototype is the use of PCR for detection of Chlamydia trachomatis in the upper urinary tract in patients with symptoms of acute pyelonephritis. The sample for the study was taken during surgery of the upper urinary tract by aspiration of urine from the renal pelvis or ureter above the level of obstruction [Dimitrakov J., V. Ganev, Zlatanov So, Detchev I, Horvat, A., S. Kirov, Vatchkova I., D. Dimitrakov PCR studies on the presence of Chlamydia trachomatis in the upper urinary tract of patients with obstructive pyelonephritis // Folia medica. - 1998. - Vol.40, No. 3. - P. 24-28]. The main disadvantages of the prototype are its invasiveness and loss of use for early, before the manifestation of clinical manifestations diagnosis of specific infectious diseases of the kidney, caused by Chlamydia trachomatis. The main problem to be solved by the invention is to provide a non-invasive and informative early, before the manifestation of clinical manifestations diagnosis of specific infectious diseases of the kidney, caused by Chlamydia trachomatis, using the definition in the urine of molecular markers. The problem is solved by the fact that you define in the urine gas chromatography and mass spectrometric methods 2-propenamide, N-amino-oxymethylene, 2-methyl-5-(1-methyl-ethyl)-phenol and 4-4-dihydroxy-diphenyl-sulfon and when the amount of 0.002-0.06 mmol/l; of 0.002-0.06 mmol/l; 0.003 to 0.11 mmol/l and of 0.002-0.05 mmol/l, respectively diagnose specific infectious pathology of the kidney, caused by Chlamydia trachomatis. As a result of our research were first identified by gas chromatography-mass spectrometry of urine parameters, showing together about the presence of infectious and chronic kidney disease caused by Chlamydia trachomatis, not only after the beginning of the manifestation of clinical manifestations of pathologists the kidneys, but before the manifestation deployed clinical manifestations of chronic kidney disease. From the patent and technical literature and practice of examination of patients with chlamydia are not aware of the method for the diagnosis of infectious renal pathology, caused by Chlamydia trachomatis, which would be identical to declare. Hence, the legitimate conclusion about conformity of the proposed solutions to the criterion "novelty". The above set of essential features necessary and sufficient for obtaining a technical result - providing non-invasive and informative early, before the manifestation of clinical manifestations diagnosis of specific infectious diseases of the kidney, caused by Chlamydia trachomatis, using the definition in the urine of molecular markers. Between the existing signs and solve problems there is a causal relationship, where each topic are needed and effect on obtaining a technical result which, together, signs sufficient to obtain it. Legitimate conclusion about conformity of the proposed technical solution the criterion of "inventive step". The proposed method can be implemented iteratively, using the inherent essential features and, hence, the proposed solution meets the criterion of "industrial applicability". The claimed invention aprobar the Vano for examination of patients with chlamydia. Below are the results of this testing. Example 1. Patient K., 24 years old with a diagnosis of urogenital chlamydia (chronic cervicitis, vulvovaginitis). On the basis of the NDP-diagnostics installed infection of lower genitourinary tract Chlamydia trachomatis. When using conventional methods of diagnosis of chronic kidney disease have been identified. As a result of further examination of the patient using the proposed method are diagnosed infectious pathology of the kidneys on the basis of the combined gas chromatography and mass spectrometric detection in the urine as molecular markers of infectious and chronic kidney disease with urogenital chlamydiosis 2-propenamide in the amount of 0.05 mmol/l, N-amino-oxyethylated in the amount of 0.06 mmol/l, 2-methyl-5-(1-methyl-ethyl)-phenol in the amount of 0.11 mmol/l, 4-4-dihydroxy-diphenyl-sulfone in the amount of 0.05 mmol/l two weeks after detection in urine diagnostically significant for infectious diseases of the kidney with urogenital chlamydiosis amounts of data of molecular markers, the patient developed the first clinical manifestations of chronic kidney disease. After conducting a comprehensive etiopathogenetic treatment (systemic and local) chlamydia using software immune clinical manifestations of chronic kidney disease? is the n, diagnostically significant for infectious diseases of the kidney with urogenital chlamydiosis number of molecular markers (2-propenamide, N-amino-oxymethylene, 2-methyl-5-(1-methyl-ethyl)-phenol and 4-4-dihydroxy-diphenyl-sulfone) in urine was not determined. Example 2. Patient K., 34 years old with a diagnosis of urogenital chlamydia (chronic cervicitis, chronic salpingoophoritis). On the basis of PCR diagnostics installed infection of lower genitourinary tract Chlamydia trachomatis. When using conventional methods of diagnosis of chronic kidney disease have been identified. As a result of further examination of the patient using the proposed method are diagnosed infectious pathology of the kidneys on the basis of the combined gas chromatography and mass spectrometric detection in the urine as molecular markers of infectious and chronic kidney disease with urogenital chlamydiosis 2-propenamide in the amount of 0.003 mmol/l, N-amino-oxyethylated in the amount of 0.002 mmol/l, 2-methyl-5-(1-methyl-ethyl)-phenol in the amount of 0.003 mmol/l, 4-4-dihydroxy-diphenyl-sulfone in the number 0,009 mmol/l one week after detection in urine diagnostically significant for infectious diseases of the kidney with urogenital chlamydiosis amounts of data of molecular markers, the patient developed clinically manifest the symptoms of chronic kidney disease. After conducting a comprehensive etiopathogenetic treatment (systemic and local) chlamydia using software immune clinical manifestations of chronic kidney disease has resolved, diagnostically significant for infectious diseases of the kidney with urogenital chlamydiosis number of molecular markers (2-propenamide, N-amino-oxymethylene, 2-methyl-5-(1-methyl-ethyl)-phenol and 4-4-dihydroxy-diphenyl-sulfone) in urine was not determined. Example 3. Patient D., 38 years old with a diagnosis of urogenital chlamydia (chronic prostatitis). On the basis of PCR diagnostics installed infection of lower genitourinary tract Chlamydia trachomatis. When using conventional methods of diagnosis of chronic kidney disease have been identified. As a result of further examination of the patient using the proposed method are diagnosed infectious pathology of the kidneys on the basis of the combined gas chromatography and mass spectrometric detection in the urine as molecular markers of infectious and chronic kidney disease with urogenital chlamydiosis 2-propenamide in the number of 0.004 mmol/l, N-amino-oxyethylated in the number 0,006 mg/DL, 2-methyl-5-(1-methyl-ethyl)-phenol in the amount of 0,007 mmol/l, 4-4-dihydroxy-diphenyl-sulfone in the number 0,008 mmol/l After conducting a comprehensive etiopathogenetic what about the treatment (systemic and local) chlamydia using software immune diagnostically significant for infectious diseases of the kidney with urogenital chlamydiosis number of molecular markers (2-propenamide, N-amino-oxymethylene, 2-methyl-5-(1-methyl-ethyl)-phenol and 4-4-dihydroxy-diphenyl-sulfone) in urine was not determined. Example 4. Patient P., 27 years old with a diagnosis of urogenital chlamydia (chronic prostatitis). On the basis of PCR diagnostics installed infection of lower genitourinary tract Chlamydia trachomatis. When using conventional methods of diagnosis of chronic kidney disease have been identified. As a result of further examination of the patient using the proposed method are diagnosed infectious pathology of the kidneys on the basis of the combined gas chromatography and mass spectrometric detection in the urine as molecular markers of infectious and chronic kidney disease with urogenital chlamydiosis 2-propenamide in the amount of 0.002 mmol/l, N-amino-oxyethylated in the number of 0.004 mmol/l, 2-methyl-5-(1-methyl-ethyl)-phenol in the amount of 0.004 mmol/l, 4-4-dihydroxy-diphenyl-sulfone in an amount of 0.004 mmol/l After conducting a comprehensive etiopathogenetic treatment (systemic and local) chlamydia using software immune diagnostically significant for infectious diseases of the kidney with urogenital chlamydiosis number of molecular markers (2-propenamide, N-amino-oxymethylene, 2-methyl-5-(1-methyl-ethyl)-phenol and 4-4-dihydroxy-diphenyl-sulfone) in urine did not define the camping. Example 5. Patient E., 61 years with a diagnosis of urogenital chlamydia (chronic prostatitis). On the basis of PCR diagnostics installed infection of lower genitourinary tract Chlamydia trachomatis. When using conventional methods of diagnosis of chronic kidney disease have been identified. As a result of further examination of the patient using the proposed method are diagnosed infectious pathology of the kidneys on the basis of the combined gas chromatography and mass spectrometric detection in the urine as molecular markers of infectious and chronic kidney disease with urogenital chlamydiosis 2-propenamide in the amount of 0.06 mmol/l, N-amino-oxyethylated in the amount of 0.04 mmol/l, 2-methyl-5-(1-methyl-ethyl)-phenol in the amount of 0.04 mmol/l, 4-4-dihydroxy-diphenyl-sulfone in the amount of 0.002 mmol/L. After conducting a comprehensive etiopathogenetic treatment (systemic and local) chlamydia using software immune diagnostically significant for infectious diseases of the kidney with urogenital chlamydiosis number of molecular markers (2-propenamide, N-amino-oxymethylene, 2-methyl-5-(1-methyl-ethyl)-phenol and 4-4-dihydroxy-diphenyl-sulfone) in urine was not determined. Thus, the examples show the advantages of the proposed technical solution in comparison with protot the POM, bringing non-invasive and informative early, before the manifestation of clinical manifestations diagnosis of specific infectious diseases of the kidney, caused by Chlamydia trachomatis, using the definition in the urine of molecular markers: 2-propenamide, N-amino-oxymethylene, 2-methyl-5-(1-methyl-ethyl)-phenol and 4-4-dihydroxy-diphenyl-sulfone. Method for the diagnosis of infectious diseases of the kidney, caused by Chlamydia trachomatis, by identifying molecular markers, characterized in that you define in the urine gas chromatography and mass spectrometric methods 2-propenamide, N-amino-oxymethylene, 2-methyl-5-(1-methyl-ethyl)-phenol and 4-4-dihydroxy-diphenyl-sulfon and when the amount of 0.002-0.06 mmol/l; of 0.002-0.06 mmol/l; 0.003 to 0.11 mmol/l and of 0.002-0.05 mmol/l, respectively diagnose specific infectious pathology of the kidney, caused by Chlamydia trachomatis.
|